CME/SAM SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission

*Victor M. Corman,*¹ *Holger F. Rabenau,*² *Ortwin Adams,*³ *Doris Oberle,*⁴ *Markus B. Funk*,⁶ *Brigitte Keller-Stanislawski,*⁴ *Jörg Timm,*³ *Christian Drosten,*^{1,5} *and Sandra Ciesek*^{2,5}

KEY IDEAS

- Oral swabs, sputum, and blood samples from 18 asymptomatic and symptomatic patients with SARS-CoV-2 infection were examined using RT-PCR testing in order to assess the risk of transfusionrelated transmission.
- In asymptomatic patients as well as patients with flulike symptoms and fever, no SARS-CoV-2 RNA could be detected in the blood or serum despite a clearly positive result in all throat swabs.
- As patients with symptoms of infectious disease will not be admitted to blood donation, the risk for transfusion transmission of SARS-CoV-2 seems to be negligible.

s of March 2020, the SARS-CoV-2 pandemic that originated in Wuhan, Hubei Province, China, is quickly spreading in many countries of the world.

Huang et al.¹ reported RNAemia in 6 of 41 symptomatic Wuhan patients (15%) with laboratory-confirmed SARS-CoV2 infection. Zhang et al.² showed for 15 Wuhan patients diagnosed with viral pneumonia caused by SARS-CoV-2 that shedding may occur through multiple routes (respiratory, fecal-oral, or body fluids); 6 out of the 15 patients (40%) were blood positives. In addition, Kim et al.³ reported on intermittently positive blood RT-PCR (real-time reverse transcription polymerase chain reaction) results in 2 SARS-CoV-2 patients in South Korea with mild and moderate symptoms.

In Germany, blood donors have to be at least 18 years old and should not be older than 65 years of age. In addition, volunteers will not be admitted to blood donation if they show signs and symptoms of an infection (e.g., fever, flu-like symptoms). With these requirements and the additional donor screening, a high national safety standard with regard to the prevention of transfusion-related viral infections has been achieved in recent years.⁴

However, with respect to the safety of blood donation, the questions arise whether Corona virus disease 2019

(Covid-19) can be transmitted through blood and how long SARS-CoV-2 positive patients with minimal symptoms have to be deferred from blood donation.

PATIENTS AND METHODS

We report on molecular detection of SARS-CoV-2 in 18 patients, 2 of whom were infected in China and evacuated to Germany on February 1.⁵ In 16 patients, the transmission in Germany is most likely.⁶ Information on the patient population was published elsewhere^{5,6} and SARS-CoV-2 testing targeting the E and RNA-dependent RNA polymerase gene was performed as previously described by Corman et al.⁷ In patients with minor symptoms, laboratory tests were carried out during the two-week quarantine period, in those with severe symptoms, tests were done during inpatient treatment.

From the ¹Institute for Virology, Charité University Hospital, Berlin; ²Institute for Medical Virology, University Hospital, Goethe University, Frankfurt; ³Institute for Virology, University Hospital Düsseldorf, Faculty of Medicine, University Düsseldorf, Düsseldorf; ⁴Department Safety of Drugs and Medical Devices, Paul-Ehrlich-Institut, Langen and ⁵German Centre for Infection Research, DZIF, Braunschweig, Germany.

Address reprint requests to: Markus B. Funk, Paul-Ehrlich-Institut, Paul-Ehrlich-Straße 51-59, 63225 Langen, Germany; e-mail: markus.funk@pei.de.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Received for publication March 17, 2020; revision received March 24, 2020, and accepted March 25, 2020.

doi:10.1111/trf.15841

© 2020 The Authors. *Transfusion* published by Wiley Periodicals, Inc. on behalf of AABB.

TRANSFUSION 2020;60;1119–1122

		TABLE	TABLE 1. Molecular detection of SARS-CoV-2 in 18 patients with asymptomatic or symptomatic infection	tion of SARS-Co	V-2 in 18 patie	nts with asym	ptomatic or syn	nptomatic	infectior	_	
	Ade	Oral swab [†] / sputum	Blood [‡]				No symptoms			Symptoms [§]	
Dationt*	18_65 vears		Number of tests	Whole blood	Serum	Plasma	Asymptomatic	Flu-like	Fever	Pneumonia	Art. ventilation
ר מווכו ור			hailiniad				- /+	- /+	- /+	- /+	
01	×	30.10	-		1 x neg.		+	I	I	I	I
02	×	24.39	7	4 x neg.	3 x neg.		+	I	I	I	I
03	×	30.25	7	4 x neg.	3 x neg.		=	I	I	I	I
04	×	32.13	9		6 x neg.		I	+	I	I	I
05	×	31.67	7		7 x neg.		I	+	I	I	I
90	×	20.06	-		1 x neg.		I	+	I	I	I
07	×	24.14	2		2 x neg.		I	+	I	I	I
08	×	27.21	-		1 x neg.		I	+	I	I	I
60	×	28.46	7		7 x neg.		I	+	I	I	I
10	×	17.44	-		1 x neg.		I	+	I	I	I
1	×	15.35	S	2x neg.	3 x neg.		I	+	+	I	I
12	×	37.32	8		8 x neg.		I	+	+	I	I
13	×	31.05	-		1 x neg.		I	+	+	I	I
14	×	28.43	2	1x neg.	1 x neg.		I	+	+	I	I
15	×	39.1	с		2 x neg.	1 x neg.	I	+	+	I	I
16	×	34.8	2			2 x neg.	I	+	+	+	I
17	×	pos. [¶]	8		4 x neg.	4 x neg.	I	+	+	+	I
18	×	22.6	8		4 x neg.	3 x neg.	I	+	+	+	+
						1 x pos.**					
	n patients infected	d in Germany, tw	Sixteen patients infected in Germany, two patients infected in (in China.							
+ RNA-N	Minimum value (max. Viral load) BNA-NAT-test method of BdBF	iral load). of BdBP (BN∆-de	Minimum value (max. Viral load). BNA-NAT-test method of BABP /BNA-denendent BNA nolvmersse dene)-Gene testing scrönding to Corman et al ⁶	srase dene)-Gene te	acting according to	o Corman at al ⁶					
	Symptoms at the time of testing	f testing.									
	sh on chest and l	egs, minimal inflé	a a	amination; afebrile	and normal vital s	igns during hospi	tal observation. ⁴				
SARS-	CoV-2 RNA (23.6 wel detection of 9	500 copies/mL) w	T SARS-CoV-2 RNA (23.600 copies/mL) was only detected in space in space in space in the second secon	n sputum from the lower respiratory tract.	er respiratory tract.						
+ = prese	int; -= absent; q	RT-PCR = quant	= present; $-$ = absent; $qRT-PCR$ = quantitative reverse transcription	is one province desired. Isociptase polymerase chain reaction; Ct = cycle threshold; ARDS = acute respiratory distress syndrome.	chain reaction; <i>Ct</i>	= cycle threshold	; ARDS = acute re	spiratory dis	stress synd	rome.	

RESULTS

Twelve of the 18 patients were males and six were females. Three patients were asymptomatic, seven presented with flu-like symptoms, five had flu-like symptoms as well as fever, two suffered from pneumonia, and one patient needed artificial respiration because of acute respiratory distress syndrome (ARDS) (Table 1). Three of the 18 patients fulfilled the requirements for blood donation in Germany. Whereas oral swabs or sputum from the lower respiratory tract were tested RT-PCR positive in all patients, RNAemia was only detected in one out of eight serum/plasma samples taken from the patient with ARDS.

DISCUSSION

We presented data on 18 SARS-CoV-2 infected patients, 3 patients without specific symptoms and 15 with symptoms of different severity. SARS-CoV-2 genomes were only detected in 1 of 77 blood samples examined. The patient with RNAemia suffered from ARDS and was artificially ventilated in an intensive care unit. In asymptomatic patients who are eligible for blood donation as well as patients with flu-like symptoms and fever, no SARS-CoV-2 RNA could be detected in the blood or serum despite a clearly positive result in all throat swabs.

Our findings are in line with published data⁸ and confirm that SARS-CoV-2 infection may go without noticeable manifestation of clinical symptoms. Furthermore, Chen et al.⁹ detected SARS-CoV-2 genome in the blood of 6 out of 57 Chinese patients and found RNAemia to be associated with a more severe clinical picture. In addition, detectable serum SARS-CoV-2 RNAemia was found to be closely linked to an elevated interleukin 6 (IL-6) level in critically ill Covid-19 patients.¹⁰

Since there is currently no recognized external standardization of the SARS-CoV-2 RT-PCR methods, a direct comparison of the results of Chinese and German studies is not possible. Of note, RNAemia is not equivalent to infectiousness, i.e., despite the presence of RNA it is unknown whether blood can harbor intact viruses that are able to infect tissues and, when transfused, can cause hematogenous transmission.

Hitherto, similarly to the other two coronaviruses that have emerged over the past 20 years (SARS, the Severe Acute Respiratory Syndrome Coronavirus^{11,12} and MERS-CoV, causing Middle East Respiratory Syndrome,¹³ no hematogenous transmissions have been documented for SARS-CoV-2.

Due to a lack of evidence indicating a risk for transfusion transmission of SARS-CoV-2, the American Association of Blood Banks (AABB), the Food and Drug Association (FDA), and the Centers for Disease Control and Prevention (CDC) are not recommending any action by blood collection establishments at this time (March 3, 2020).¹⁴ Our data support this recommendation.

CONCLUSION

Among 18 patients with RT-PCR confirmed SARS-CoV-2 infection included in our study only one critically ill individual had RNAemia. Based on these limited data, there is no measurable risk for SARS-CoV-2 transmission through blood components in asymptomatic SARS-CoV-2 infected individuals. As no cases of transmission due to transfusion of blood products have been reported for SARS, MERS-CoV, and SARS-CoV-2, and considering that patients with symptoms of infectious disease will not be admitted to blood donation in Germany, the risk for transfusion transmission of SARS-CoV-2 is supposed to be negligible. However, well-powered studies are needed to further evaluate the potential risk of hematogenous transmission and to determine the appropriate referral time for blood donation of recovered SARS-CoV-2 patients.

CONFLICT OF INTEREST

The authors have disclosed no conflicts of interest.

REFERENCES

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
- 2. Zhang W, Du R-H, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9:386-9.
- Kim JY, Ko JH, Kim Y, et al. Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. J Korean Med Sci 2020; 35:e86.
- Funk MB, Heiden M, Müller S, et al. Haemovigilance reports of the Paul-Ehrlich-Institut. [cited 2020 March 13]. Available from www.pei.de/haemovigilance-report.
- Hoehl S, Rabenau H, Berger A, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med 2020;382:1278-80.
- Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970-1.
- Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020;25:2000045.
- Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis 2020;20: 410-1.
- Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect 2020;9:469-73.

- Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis 2020. pii: ciaa449. https://doi.org/10.1093/cid/ciaa449. [Epub ahead of print].
- Centers for Disease Control and Prevention (CDC). Outbreak of severe acute respiratory syndrome-worldwide, 2003. MMWR Morb Mortal Wkly Rep 2003;52:226-8.
- Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76.
- 13. Mackay IM, Arden KE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J 2015;12:222.
- American Association of Blood Banks (AABB). Coronavirus and Blood donation - talking points. [cited 2020 March 10]. Available from http://www.aabb.org/advocacy/regulatorygovernment/ Pages/Coronavirus-and-Blood-Donation-Talking-Points.aspx.